| scholarly article | Q13442814 |
| P2093 | author name string | Wooley PH | |
| Widmer MB | |||
| Gillis S | |||
| Dutcher J | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 6602-6607 | |
| P577 | publication date | 1993-12-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice | |
| P478 | volume | 151 |
| Q71576582 | 3rd International Symposium on the Immunotherapy of the Rheumatic Diseases. 10-14 May 1995, Cyprus. Abstracts |
| Q81786169 | A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China |
| Q54761549 | A randomized, controlled trial of efficacy and safety of Anbainuo, a bio-similar etanercept, for moderate to severe rheumatoid arthritis inadequately responding to methotrexate. |
| Q95780698 | An Endogenous TNF-α Antagonist Induced by Splice-switching Oligonucleotides Reduces Inflammation in Hepatitis and Arthritis Mouse Models |
| Q37165337 | An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models |
| Q36271120 | Analysing the effect of novel therapies on cytokine expression in experimental arthritis |
| Q24801075 | Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice |
| Q24805245 | Anti-cytokine therapy in chronic destructive arthritis |
| Q57351157 | Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats |
| Q39841074 | Anticytokine therapy for periodontal diseases: Where are we now? |
| Q34071312 | Arguments for interleukin 1 as a target in chronic arthritis |
| Q37728305 | BF02, a recombinant TNFR2 fusion protein, alleviates adjuvant arthritis by regulating T lymphocytes in rats |
| Q77627751 | Biological insights from clinical trials with anti-TNF therapy |
| Q34071308 | Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha |
| Q41832023 | Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats. |
| Q36371110 | Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis |
| Q34731287 | Current and future management approaches for rheumatoid arthritis |
| Q39645825 | Deletion of P2Y2 receptor reveals a role for lymphotoxin-α in fatty streak formation |
| Q39714043 | Destructive arthritis in vaccinated interferon gamma-deficient mice challenged with Borrelia burgdorferi: modulation by tumor necrosis factor alpha |
| Q60937751 | Development of a Novel Diagnostic Biomarker Set for Rheumatoid Arthritis Using a Proteomics Approach |
| Q38357414 | Divergent roles for p55 and p75 TNF-alpha receptors in the induction of plasminogen activator inhibitor-1. |
| Q45861247 | Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-4 or IL-13 ameliorates murine collagen-induced arthritis (CIA). |
| Q34071287 | Etanercept (Enbrel): update on therapeutic use |
| Q35638509 | Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis |
| Q33684274 | Etanercept: a review of its use in rheumatoid arthritis |
| Q34991484 | Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis |
| Q36025268 | Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif |
| Q42844958 | GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice |
| Q24796801 | Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients? |
| Q43053667 | Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice |
| Q37243199 | Immune and inflammatory role in renal disease. |
| Q33287342 | Immunomodulation of murine collagen-induced arthritis by N, N-dimethylglycine and a preparation of Perna canaliculus |
| Q46360455 | Inhibition of tumor necrosis factor-alpha action within the CNS markedly reduces the plasma adrenocorticotropin response to peripheral local inflammation in rats. |
| Q35630027 | Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases |
| Q39246542 | Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability. |
| Q34224384 | Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis |
| Q42840040 | Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice |
| Q40653702 | Involvement of tumor necrosis factor-alpha in glomerular injury |
| Q77627736 | Joint inflammation and cartilage destruction may occur uncoupled |
| Q34775626 | Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis |
| Q54614405 | Local gene transfer of OPG prevents joint damage and disease progression in collagen-induced arthritis. |
| Q36067667 | Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors |
| Q45885757 | Modulation of proinflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13. |
| Q35669716 | Neutralization of tumor necrosis factor bioactivity ameliorates urethane-induced pulmonary oncogenesis in mice |
| Q34600147 | Oral administration of milk fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 to DBA/1 mice inhibits secretion of proinflammatory cytokines |
| Q35612503 | Osteoarticular Expression of Musashi-1 in an Experimental Model of Arthritis |
| Q34449130 | Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis |
| Q34274075 | Pharmacotherapy for uveitis: current management and emerging therapy |
| Q28570898 | RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies |
| Q41994795 | Ratio of neutrophil/lymphocyte and platelet/lymphocyte in patient with ankylosing spondylitis that are treating with anti-TNF |
| Q37353748 | Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. |
| Q28535046 | Retracted: The Effect of Soluble RAGE on Inhibition of Angiotensin II-Mediated Atherosclerosis in Apolipoprotein E Deficient Mice |
| Q36760300 | Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis |
| Q33782333 | Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1beta in chronicity and cartilage destruction |
| Q38755912 | Selected cytokine pathways in rheumatoid arthritis |
| Q36028645 | Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. |
| Q72238634 | Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4 |
| Q34162687 | Synthesis of novel tylophorine derivatives and evaluation of their anti-inflammatory activity |
| Q35553022 | TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis |
| Q34501230 | Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis. |
| Q39683541 | Temporary blockade of the tumor necrosis factor receptor signaling pathway impedes the spread of scrapie to the brain |
| Q43494262 | The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis |
| Q40859444 | The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis |
| Q77982884 | The in vivo effects of tumour necrosis factor blockade on the early cell mediated immune events and syndrome expression in rat adjuvant arthritis |
| Q34027484 | The role of tumor necrosis factor alpha in the pathophysiology of congestive heart failure |
| Q82877041 | Therapeutic effects of TACI-Ig on rat with adjuvant arthritis |
| Q77627754 | Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody |
| Q36569960 | Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription |
| Q35554897 | Tumour necrosis factor receptor gene therapy affects cellular immune responses in collagen induced arthritis in mice. |
Search more.